Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Frequently asked questions
What sector does Aldeyra The (ALDX) operate in?
Aldeyra The belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Aldeyra The (ALDX) current stock price?
As of the latest data, Aldeyra The stock price is $1.52, with a previous close of $1.51. Aldeyra The gained $0.01 in the last trading session, representing a 0.66% increase.
What is Aldeyra The (ALDX) current market capitalization?
Aldeyra The market cap is approximately 91.70 million.
What is Aldeyra The (ALDX) Earnings Per Share (EPS)?
The trailing EPS is -$0.44, and the forward EPS is -$0.23.
What is Aldeyra The (ALDX) EBITDA?
Aldeyra The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -5.85 trillion.
Does Aldeyra The (ALDX) pay dividends?
No. Aldeyra The does not pay a dividend.
What is Aldeyra The (ALDX) beta (volatility) score?
Aldeyra The has a beta of 1.198, meaning its volatility is roughly in line with the market.
